Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ND-003
- Development stage
- Phase 1
- Lead developer
- Shenzhen NewDEL Biotech
- Modality
- Small Molecules
- Administration
- Oral, Topical, Inhalation
01
Overview
ND-003 is an investigational oral small-molecule kinase inhibitor jointly developed by Shenzhen NewDEL Biotech and Shenzhen Small Molecule Drug Innovation Center. It inhibits neurotrophic receptor tyrosine kinases and RET. The program includes a phase 1 study in advanced solid tumors and a phase 2 proof-of-concept study in idiopathic pulmonary fibrosis. Renal fibrosis and atopic dermatitis have also been identified as development indications. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06169579))
02
Targets
Trk (Trk receptor family)RET (Rearranged during transfection receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on ND-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ND-003.